Human iPSC neurons provide robust solutions to predict drug-induced disruption of electrical, structural, and functional processes.
Neurotoxicity has been difficult to detect with traditional methods and remains a primary cause of late-stage and post-launch drug attrition. The iCell® portfolio of subtype-specific human neurons provides new models for early and accurate detection of multiple forms of neurotoxicity. This seminar will focus on CDI’s iCell GABANeurons and iCell GlutaNeurons as tools for detecting structural (neurite outgrowth) and electrical (seizurogenesis) toxicities as well as turnkey approaches for phenotypic profiling using artificial intelligence-based analysis of microelectrode array (MEA) data developed at NeuroProof.
This webinar will provide:
- An overview of the iCell human neuronal portfolio
- Case-study and data-driven examples of its use in neurotoxicity applications
- The advantages of phenotypic screening and classification
- Turnkey approaches to outsourcing neurotoxicity detection